Fenofibrate in patients with cervical intraepithelial neoplasia and invasive cervical carcinoma
1-800-641-2422
Window of Opportunity Trial of Fenofibrate in Patients with High-grade Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma
- Sex at Birth: Any
- Age: Adult (18 - 64), Older Adult (65+)
- Accepting Healthy People: No
- Type: Interventional / Therapeutic
- Trial Phase: Phase I
- Conditions Being Studied: Cancer - Cervical
Study Purpose
Normally, p53 helps prevent tumors from forming in the body. Early studies have shown that Fenofibrate, a cholesterol-lowering drug, can restore normal function to p53 and can change the metabolism of HPV-positive tumors in a way that stops the growth of tumors. The purpose of this study is to understand how Fenofibrate can be used to treat HPV-positive cervical cancers and cervical dysplasia. Researchers will examine collected tissue samples and investigate various genes and proteins to see whether Fenofibrate has an effect on HPV-positive cervical cancers and cervical dysplasia.
Locations
UH Seidman Cancer Center
11100 Euclid Avenue
Cleveland OH, 44106
- UH IRB: STUDY20240745
- StudyID: CASE3822
- ClinicalTrials.gov: NCT06191133
1-800-641-2422
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422